Development of a Novel Anti—CD44 Monoclonal Antibody for Multiple Applications against Esophageal Squamous Cell Carcinomas

Nohara Goto 1,2, Hiroyuki Suzuki 1,*, Teizo Asano 3, Tomohiro Tanaka 3, Mika K. Kaneko 3, and Yukinari Kato 1,3,*

1 Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan; s19305506s@tsukuba.ac.jp
2 Ph.D. Program in Human Biology, School of Integrative and Global Majors, University of Tsukuba, Tsukuba 305-8575, Japan
3 Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan; tomohiro.tanaka.b5@tohoku.ac.jp (T.T.); teizo.asano.a7@tohoku.ac.jp (T.A.); k.mika@med.tohoku.ac.jp (M.K.K.)
* Correspondence: hiroyuki.suzuki.b4@tohoku.ac.jp (H.S.); yukinari.kato.e6@tohoku.ac.jp (Y.K.)

Abstract: CD44 is a cell surface glycoprotein, which is expressed on normal cells, and overexpressed on cancer cells. CD44 is involved in cell adhesion, migration, proliferation, survival, stemness, and chemoresistance. Therefore, CD44 is thought to be a promising target for cancer diagnosis and therapy. In this study, we established anti—CD44 monoclonal antibodies (mAbs) by immunizing mice with a CD44 variant (CD44v3—10) ectodomain and screening using enzyme—linked immunosorbent assay. We then characterized them using flow cytometry, Western blotting, and immunohistochemistry. One of the established clones (C44Mab—46; IgG1, kappa) reacted with CD44 standard isoform (CD44s)—overexpressed Chinese hamster ovary—K1 cells (CHO/CD44s) or esophageal squamous cell carcinoma (ESCC) cell lines (KYSE70 and KYSE770). The apparent Km of C44Mab—46 for CHO/CD44s, KYSE70, and KYSE770 was 1.1 × 10−8 M, 4.9 × 10−8 M, and 4.1 × 10−8 M, respectively. C44Mab—46 and 46 detected CD44s of CHO/CD44s and KYSE70, and CD44 variants of KYSE770 in Western blot analysis. Furthermore, C44Mab—46 strongly stained the formalin—fixed paraffin—embedded ESCC tissues in immunohistochemistry. Collectively, C44Mab—46 is very useful for detecting CD44 in various applications.

Keywords: CD44; monoclonal antibody; esophageal cancer

1. Introduction

CD44 is a cell surface glycoprotein, which is expressed on normal cells, and overexpressed on cancer cells. [1]. The CD44 gene is comprised of 19 exons in human [2]. The first five and the last five exons are constant and encode the shortest isoform of CD44 (85—95 kDa), called the CD44 standard isoform (CD44s). CD44s is widely distributed and plays critical roles in normal homeostasis, including hematopoiesis and immune system, and organogenesis [3]. The middle nine exons can be alternatively spliced and assembled with the ten exons contained in CD44s. They are referred to as CD44 variant isoforms (CD44v) [4]. For instance, CD44v3—10 is expressed in epithelial tissues and overexpressed in carcinomas [3]. Furthermore, CD44v3—10 functions as a co—receptor of receptor tyrosine kinases by binding to heparin—binding epidermal growth factor—like growth factor and fibroblast growth factors (via v3—encoded region) [5] and hepatocyte growth factor (via v6—encoded region) [6], and confers oxidative stress resistance via v8—10—encoded region [7]. Moreover, both CD44s and CD44v are major receptors for hyaluronic acid (HA), which is involved in cell adhesion, migration, and proliferation [8]. They also play...
important roles in tumor progression, metastasis, stemness, and resistance to chemotherapy and radiotherapy [9,10]. Therefore, CD44 is a promising target for cancer diagnosis and therapy.

Several CD44-targeting monoclonal antibodies (mAbs) have been developed for preclinical research applications. IM7 mAb was shown to inhibit HA-induced vascular endothelial growth factor production in human vascular endothelial cells [11] and significantly decrease cell migration and invasion in breast cancer cells [12]. Another mAb, H4C4 mAb, was found to reduce tumor growth, metastasis, and post-radiation recurrence [13]. A humanized mAb specific for CD44, RG7356, has been found to be directly cytotoxic for leukemia B cells, but with no effect on normal B cells. Administration of RG7356 to immune-deficient mice engrafted with human chronic lymphocytic leukemia cells was found to result in complete clearance of engrafted leukemia cells [14]. Finally, CD44v6-specific humanized mAbs (BIWA4 and BIWA8) labeled with $^{186}$Re showed the therapeutic efficacy in head and neck SCC xenograft bearing nude mice in another study [15].

Sulfasalazine is an inhibitor of xCT, the subunit of cystine–glutamate transporter. CD44v has been found to interact with the xCT and promotes oxidative stress resistant in cancer cells [7,16]. The clinical trials of sulfasalazine have been evaluated in combination with cisplatin in patients with CD44v-positive advanced gastric cancer refractory to cisplatin [17], and the reduction of the CD44v-positive gastric cancer cells was observed in sulfasalazine treated patients [18]. These results suggest that CD44v is an important marker to predict and evaluate the sensitivity of sulfasalazine.

Previously, we established the novel mAb, C44Mab−5 (IgG1, kappa) against CD44 using the Cell-Based Immunization and Screening method [19]. C44Mab−5 showed high sensitivity for flow cytometry and immunohistochemical analysis in oral cancers. In this study, we developed a novel anti-CD44 mAb, C44Mab−46 (IgG1, kappa), and evaluated it for various applications, including flow cytometry, Western blotting, and immunohistochemical analyses.

2. Results

2.1. Flow Cytometric Analysis of C44Mab−46 to CD44 Expressing Cells

In this study, C44Mab−46 was established by immunizing one mouse with human CD44v3−10 ectodomain (Figure 1). We already confirmed the epitope of C44Mab−46 as 174−TDDDV−178 [20,21] encoded within the first five exons, indicating that C44Mab−46 recognizes CD44 standard isoforms (CD44s). Therefore, we confirmed the reactivity of C44Mab−46 against CHO/CD44s by flow cytometry. As shown in Figure 2A, C44Mab−46 recognized CHO/CD44s cells in a dose dependent manner, but not CHO-K1 cells (Figure 2B). The recognition of CHO/CD44s by C44Mab−46 was strongly inhibited by CD44 peptide (amino acids 161−180, WT), which contains 174−TDDDV−178 sequence. However, the D175A mutant peptide, which could not be recognized by C44Mab−46 [21], never inhibited (Figure 2C). Furthermore, C44Mab−46 also recognized endogenous CD44 in the context of ESCC cell lines as it reacted with both KYSE 70 and KYSE770 in a dose-dependent manner (Figure 2D, E).

Next, we assessed the binding affinity of C44Mab−46 with CHO/CD44s, KYSE70, and KYSE770 using flow cytometry. The apparent $K_D$ of C44Mab−46 for CHO/CD44s, KYSE70, and KYSE770 was $1.1 \times 10^{-8} \text{M}$, $4.9 \times 10^{-8} \text{M}$, and $4.1 \times 10^{-8} \text{M}$, respectively, indicating that C44Mab−46 possesses moderate affinity for CD44s-expressing cells (Figure 3).
1. Immunization of purified CD44ec (CD44v3-10 ectodomain)

Splenocytes (B cells)

Myelomas

Fusion (to 96 well plates)

2. Hybridomas production

Spleen

Purified CD44v3-10 ectodomain

3. Screening of supernatants by flow cytometry

1st screening: ELISA

2nd screening: Flow cytometry

Positive wells

CD44v3-10-expressing cells

4. Cloning of hybridomas

Establishment of anti-CD44 mAb-producing clones

Figure 1. A schematic procedure of anti–human CD44 mAbs production. A BALB/c mouse was intraperitoneally immunized with the purified CD44v3–10 ectodomain. The screening was then conducted by ELISA using the purified CD44v3–10 ectodomain, flow cytometry using parental and CD44v3–10–overexpressed CHO–K1 cells.
Figure 2. Flow cytometry to CD44 expressing cells using C44Mab−46. (A,B) CHO/CD44s (A) and CHO−K1 (B) cells were treated with 0.01–10 µg/mL of C44Mab−46, followed by treatment with Alexa Fluor 488−conjugated anti−mouse IgG. (C) C44Mab−46 (1 µg/mL), C44Mab−46 (1 µg/mL) plus human CD44 peptide (161−180 amino acids, WT) or alanine−substituted peptide (D175A) (10 µg/mL), and control (blocking buffer) were reacted with CHO/CD44 cells for 30 min at 4 °C, followed by treatment with Alexa Fluor 488−conjugated anti−mouse IgG. (D,E) KYSE70 (D) and KYSE770 (E) cells were treated with 0.01–10 µg/mL of C44Mab−46, followed by treatment with Alexa Fluor 488−conjugated anti−mouse IgG. The black line represents the negative control (blocking buffer).
Figure 3. The determination of the binding affinity of C44Mab−46. CHO/CD44s (A), KYSE70 (B), and KYSE770 (C) cells were suspended in 100 µL serially diluted C44Mab−46 (0.08 to 1300 nM). Then, cells were treated with Alexa Fluor 488−conjugated anti−mouse IgG. Fluorescence data were subsequently collected, followed by the calculation of the apparent dissociation constant (K_D) by GraphPad PRISM 8.

2.2. Western Blot Analysis

Western blotting was performed to further assess the sensitivity of C44Mab−46. Lysates of CHO−K1 and CHO/CD44s cells were probed. As shown in Figure 4A, C44Mab−46 detected CD44s as a ~85 kDa band. However, C44Mab−46 did not detect any band from lysates of CHO−K1 cells. These results indicated that C44Mab−46 specifically detect exogenous CD44s. Next, we examined the detection of endogenous CD44 using lysates
from KYSE70 and KYSE770 cells. As shown in Figure 4B, C_{44}Mab–46 could detect CD44 as 85 and 48kDa double bands from lysates of KYSE70 cells. In contrast, C_{44}Mab–46 could detect CD44 as more than 100 kDa triplet bands, probably CD44v isoforms, from lysates of KYSE770 cells. We also performed the peptide blocking experiment and found that 85 kDa band in CHO/CD44s (Figure 4C), 85 and 48 kDa bands in KYSE70, and CD44v isoforms in KYSE770 (Figure 4D) were blocked in the presence of the CD44 peptide (amino acids 161–181, WT). These results suggest that C_{44}Mab–46 recognizes endogenous CD44s and CD44v(s) in the esophageal cancer cell lines.

Figure 4. Western blotting by C_{44}Mab–46. (A) Cell lysates of CHO–K1 and CHO/CD44s (10 µg) were electrophoresed and transferred onto polyvinylidene fluoride (PVDF) membranes. The membranes were incubated with 1 µg/mL of C_{44}Mab–46 and 1 µg/mL of anti–β–actin and subsequently with peroxidase–conjugated anti–mouse immunoglobulins. (B) Cell lysates of KYSE70 and KYSE770 (10 µg) were electrophoresed and transferred onto PVDF membranes. The membranes were incubated with 1 µg/mL of C_{44}Mab–46 and 1 µg/mL of anti–β–actin and subsequently with peroxidase–conjugated anti–mouse immunoglobulins. (C) Cell lysates of CHO–K1 and CHO/CD44s (10 µg) were electrophoresed and transferred onto PVDF membranes. The membranes were incubated with 1 µg/mL of C_{44}Mab–46 and C_{44}Mab–46 (1 µg/mL) plus the CD44 peptide
(10 µg/mL, WT), and subsequently with peroxidase−conjugated anti−mouse immunoglobulins. 

(D) Cell lysates of KYSE70 and KYSE770 (10 µg) were electrophoresed and transferred onto PVDF membranes. The membranes were incubated with 1 µg/mL of C44Mab−46 and C44Mab−46 (1 µg/mL) plus the CD44 peptide (10 µg/mL, WT), and subsequently with peroxidase−conjugated anti−mouse immunoglobulins. Black arrows indicate the predicted size of CD44s (~85 kDa). The red arrow indicates the CD44 variants.

2.3. Immunohistochemical Analysis Using C44Mab−46 against ESCC Tissues

To investigate whether C44Mab−46 can be used for immunohistochemical analyses using paraffin−embedded tumor sections, we used tissue microarray of ESCC. In a well differentiated ESCC section (Figure 5A–F), C44Mab−46 strongly stained ESCC cells (Figure 5A). A clear membrane staining in ESCC was observed (Figure 5B). Hematoxylin and eosin (HE) staining was performed using the serial sections (Figure 5E,F). In an ESCC section with stromal invaded phenotype (Figure 5G–L), C44Mab−46 strongly stained stromal invaded ESCC (Figure 5G,H). HE staining was also performed using the serial sections (Figure 5K,L). Additionally, C44Mab−46 also stained at basal layer and several layers above in normal squamous epithelium of esophagus (Supplemental Figure S1). We also performed the peptide blocking experiment and found that the recognition of ESCC tissues by C44Mab−46 was completely blocked by CD44 peptide (amino acids 161−180, WT) (Supplemental Figure S2). In immunohistochemical analyses using C44Mab−46 against ESCC tissue microarrays (Table 1), C44Mab−46 stained 63 of 67 (94.0%) cases of ESCC. These results indicated that C44Mab−46 is useful for immunohistochemical analysis of paraffin−embedded tumor sections.

Table 1. Immunohistochemical analysis using C44Mab−46 against ESCC tissues.

| Case No. | Age | Sex | Organ/Anatomic Site | Pathology diagnosis | Grade | Type | Intensity |
|----------|-----|-----|---------------------|---------------------|-------|------|-----------|
| 1        | 52  | M   | Esophagus           | Squamous cell carcinoma | I     | malignant | ++        |
| 2        | 62  | F   | Esophagus           | Squamous cell carcinoma | I     | malignant | ++        |
| 3        | 54  | M   | Esophagus           | Squamous cell carcinoma | I     | malignant | ++        |
| 4        | 59  | M   | Esophagus           | Squamous cell carcinoma | I     | malignant | +         |
| 5        | 60  | M   | Esophagus           | Squamous cell carcinoma | II    | malignant | ++        |
| 6        | 66  | M   | Esophagus           | Squamous cell carcinoma | –     | malignant | –         |
| 7        | 36  | M   | Esophagus           | Squamous cell carcinoma | I     | malignant | ++        |
| 8        | 55  | F   | Esophagus           | Squamous cell carcinoma | I     | malignant | –         |
| 9        | 59  | F   | Esophagus           | Squamous cell carcinoma | I−II  | malignant | ++        |
| 10       | 48  | M   | Esophagus           | Squamous cell carcinoma | I−II  | malignant | ++        |
| 11       | 41  | M   | Esophagus           | Squamous cell carcinoma | I     | malignant | ++        |
| 12       | 58  | M   | Esophagus           | Squamous cell carcinoma | I     | malignant | ++        |
| 13       | 56  | M   | Esophagus           | Squamous cell carcinoma | I     | malignant | ++        |
| 14 (Figure 5G–L) | 72  | F   | Esophagus           | Squamous cell carcinoma | I     | malignant | +++       |
| 15       | 41  | M   | Esophagus           | Squamous cell carcinoma | I−II  | malignant | +++       |
| 16       | 50  | M   | Esophagus           | Squamous cell carcinoma | I     | malignant | –         |
| 17       | 48  | M   | Esophagus           | Squamous cell carcinoma | I     | malignant | –         |
| 18       | 55  | M   | Esophagus           | Squamous cell carcinoma | I−II  | malignant | ++        |
| 19       | 61  | F   | Esophagus           | Squamous cell carcinoma | II    | malignant | +         |
| 20       | 35  | M   | Esophagus           | Squamous cell carcinoma | I     | malignant | ++        |
| 21       | 72  | M   | Esophagus           | Squamous cell carcinoma | I     | malignant | ++        |
| 22       | 70  | M   | Esophagus           | Squamous cell carcinoma | –     | malignant | +++       |
| 23       | 42  | F   | Esophagus           | Squamous cell carcinoma | I     | malignant | ++        |
| 24       | 53  | M   | Esophagus           | Squamous cell carcinoma | I     | malignant | ++        |
| 25       | 54  | M   | Esophagus           | Squamous cell carcinoma | I−II  | malignant | ++        |
| 26 (Figure 5A–F) | 54  | F   | Esophagus           | Squamous cell carcinoma | I−II  | malignant | +++       |
Table 1. Cont.

| Case No. | Age | Sex | Organ/Anatomic Site | Pathology diagnosis | Grade  | Type      | Intensity |
|----------|-----|-----|---------------------|---------------------|--------|-----------|-----------|
| 27       | 65  | F   | Esophagus           | Squamous cell carcinoma | I – II | malignant | ++        |
| 28       | 63  | F   | Esophagus           | Squamous cell carcinoma | I – II | malignant | +++       |
| 29       | 62  | M   | Esophagus           | Squamous cell carcinoma | II    | malignant | +++       |
| 30       | 63  | M   | Esophagus           | Squamous cell carcinoma | II    | malignant | +         |
| 31       | 65  | M   | Esophagus           | Squamous cell carcinoma | II    | malignant | ++        |
| 32       | 64  | F   | Esophagus           | Squamous cell carcinoma | II    | malignant | ++        |
| 33       | 71  | M   | Esophagus           | Squamous cell carcinoma | II    | malignant | +++       |
| 34       | 55  | M   | Esophagus           | Squamous cell carcinoma | II    | malignant | +++       |
| 35       | 57  | M   | Esophagus           | Squamous cell carcinoma | II    | malignant | +++       |
| 36       | 56  | M   | Esophagus           | Squamous cell carcinoma | II    | malignant | +++       |
| 37       | 60  | M   | Esophagus           | Squamous cell carcinoma | II – III | malignant | +++       |
| 38       | 61  | F   | Esophagus           | Squamous cell carcinoma | II    | malignant | ++        |
| 39       | 61  | M   | Esophagus           | Squamous cell carcinoma | II – III | malignant | +++       |
| 40       | 50  | M   | Esophagus           | Squamous cell carcinoma | II    | malignant | +         |
| 41       | 66  | M   | Esophagus           | Squamous cell carcinoma | II    | malignant | +++       |
| 42       | 45  | M   | Esophagus           | Squamous cell carcinoma | II    | malignant | +         |
| 43       | 68  | M   | Esophagus           | Squamous cell carcinoma | II    | malignant | +++       |
| 44       | 58  | M   | Esophagus           | Squamous cell carcinoma | II    | malignant | +++       |
| 45       | 57  | M   | Esophagus           | Squamous cell carcinoma | II – III | malignant | ++        |
| 46       | 54  | F   | Esophagus           | Squamous cell carcinoma | II    | malignant | +         |
| 47       | 48  | M   | Esophagus           | Squamous cell carcinoma | II    | malignant | +++       |
| 48       | 68  | M   | Esophagus           | Squamous cell carcinoma | II    | malignant | +         |
| 49       | 54  | M   | Esophagus           | Squamous cell carcinoma | II    | malignant | +++       |
| 50       | 70  | M   | Esophagus           | Squamous cell carcinoma | III   | malignant | +++       |
| 51       | 72  | M   | Esophagus           | Squamous cell carcinoma | III   | malignant | ++        |
| 52       | 62  | M   | Esophagus           | Squamous cell carcinoma | III   | malignant | –         |
| 53       | 63  | M   | Esophagus           | Squamous cell carcinoma | II – III | malignant | ++        |
| 54       | 49  | F   | Esophagus           | Squamous cell carcinoma | II – III | malignant | ++        |
| 55       | 53  | F   | Esophagus           | Squamous cell carcinoma | II – III | malignant | ++        |
| 56       | 61  | M   | Esophagus           | Squamous cell carcinoma | III   | malignant | +++       |
| 57       | 61  | M   | Esophagus           | Squamous cell carcinoma | II    | malignant | +++       |
| 58       | 59  | F   | Esophagus           | Squamous cell carcinoma | III   | malignant | +++       |
| 59       | 62  | M   | Esophagus           | Squamous cell carcinoma | II – III | malignant | +++       |
| 60       | 56  | M   | Esophagus           | Squamous cell carcinoma | III   | malignant | +++       |
| 61       | 73  | F   | Esophagus           | Squamous cell carcinoma | II – III | malignant | +++       |
| 62       | 57  | M   | Esophagus           | Squamous cell carcinoma | II – III | malignant | +++       |
| 63       | 64  | M   | Esophagus           | Squamous cell carcinoma | III   | malignant | +++       |
| 64       | 60  | M   | Esophagus           | Squamous cell carcinoma | II – III | malignant | +++       |
| 65       | 66  | M   | Esophagus           | Squamous cell carcinoma | III   | malignant | +++       |
| 66       | 67  | M   | Esophagus           | Squamous cell carcinoma | II – III | malignant | +++       |
| 67       | 75  | M   | Esophagus           | Squamous cell carcinoma | III   | malignant | +++       |
Figure 5. Immunohistochemical analysis using C44Mab−46 against ESCC tissues. (A–D, G–J) After antigen retrieval, sections were incubated with 5 µg/mL of C44Mab−46 or negative control (blocking buffer) followed by treatment with the Envision+ kit. Color was developed using DAB, and sections were counterstained with hematoxylin. (E, F, K, L) Hematoxylin and eosin (HE) staining. Scale bar = 100 µm.
3. Discussion

CD44 have functions in many processes in normal cells (hematopoietic, immune system, and organogenesis), and in pathological situations (inflammation and cancer) [3]. CD44 exhibits passive ligand binding, including adhesion to hyaluronan and other components of the extracellular matrix. Furthermore, CD44 acts as a co-receptor for growth factors and as a scaffold for enzymes. Therefore, establishment and characterization of anti–CD44 mAbs are thought to be important for the development of CD44 targeting therapy and diagnosis.

In this study, we developed C44Mab−46, which can recognize all isoforms of CD44, and shows utility in flow cytometry, Western blotting, and immunohistochemistry applications. As shown in Figure 2, C44Mab−46 similarly recognized endogenous CD44 of KYSE70 and KYSE770 cells by flow cytometry; however, the expression pattern of CD44s and CD44v was different in Western blot analysis (Figure 4). Furthermore, we detected a 48 kDa band in KYSE70 cells, which is also blocked by the CD44 peptide (Figure 4D). By the radio labeled CD44s pulse chasing assay, a CD44s precursor form (about 48 kDa) was first translated, after which the precursor received N− and O−glycosylation and reached 85 kDa mature form [22]. This result suggests that the 48 kDa band is a non−glycosylated precursor form of CD44 in KYSE70 cells. We previously determined the epitope of C44Mab−46 as TDDDV−174−TDDDV−178 by enzyme−linked immunosorbent assay using synthetic peptides [21]. Although the Thr174 of CD44 have been confirmed as an O−glycan site [23], C44Mab−46 could recognize the epitope in the absence of glycosylation. In the future, it should be determined whether the 48 kDa CD44 is exposed on cell surface, and O−glycosylation at Thr174 affect the recognition by C44Mab−46. In KYSE770 cells, C44Mab−46 could recognize the triple bands, suggesting the expression of variant isoforms of CD44. Compared to previously established CD44 mAb C44Mab−5, C44Mab−46 tended to show the high reactivity to detect endogenous CD44 in Western blotting.

CD44s and CD44v interact with various proliferation−, migration− and invasion−promoting membrane proteins. CD44 binds to platelet−derived growth factor β−receptor and transforming growth factor−β type 1 receptor [24], and modulates their functions. CD44s also interacts with podoplanin (PDPN) and colocalizes at cell−surface protrusions. PDPN−induced migration requires CD44 in MDCK cells, and knockdown of CD44 and PDPN in oral SCC cells affect cell spreading, suggesting that CD44 directly interacts with PDPN and modulates the intracellular signaling and cell migration [25]. It is interesting that C44Mab−46 inhibits these protein−protein interactions and influences their functions.

CD44v6 is highly expressed in many cancers, and acts as co−receptor for at least three receptor tyrosine kinases (c−Met [26,27], EGFR [28], and VEGFR−2 [29]), which contribute to the oncogenic functions of CD44v6. Therefore, humanized anti−CD44v6 mAb BIWA4 (bivatuzumab)−mertansine drug conjugate, was evaluated in clinical trials [30]. However, the clinical trials were discontinued because of the severe skin toxicities [31,32]. A first−in−human phase I clinical trial with RG7356, targeting to the constant region of CD44, showed an acceptable safety profile in patients with advanced CD44−expressing solid tumors. However, the study was terminated due to no evidence of a clinical and/or pharmacodynamic dose−response relationship with RG7356, but not due to safety concerns [33]. Therefore, the development of anti−CD44 targeting mAbs with more potent and fewer side effects is desired.

We previously established cancer−specific mAbs (CasMabs) targeting to PDPN [34−37] and podocalyxin [38], which are expressed on many cancers, including ESCC [39−42]. These CasMabs recognize cancer−specific aberrant glycosylation of the target proteins [43]. It is worthwhile to develop a cancer−specific anti−CD44 antibody using the CasMab method. We used the glioblastoma LN229−secreted CD44v3−10 ectodomain as an antigen and generated many mAbs other than C44Mab−46. We selected the mAbs, which react with cancer cells, but not with normal cells by flow cytometry and immunohistochemistry. Furthermore, we previously converted the IgG1 subclass of C44Mab−5 into a mouse IgG2a, named 5−mG2a, and produced a defucosylated version, 5−mG2a−f. The 5−mG2a−f ex-
hibited ADCC/CDC activities in vitro and significantly reduced tumor growth in oral cancer cells [44]. Therefore, the production of a class switched and defucosylated version of C44Mab−46 is warranted to evaluate the in vivo anti-tumor activity. Since KYSE70 was used in this study, it was reported to be tumorigenic in athymic nude mice [45]; the cell line can be used to evaluate the anti-tumor activity as in the in vivo model.

4. Materials and Methods

4.1. Cell Lines

Mouse multiple myeloma P3X63Ag8U.1 (P3U1), a glioblastoma cell line (LN229) [46], and CHO−K1 cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Esophageal squamous cell carcinoma (ESCC) cell lines, KYSE70 and KYSE770 were obtained from the Japanese Collection of Research Bioresources (Osaka, Japan).

Human CD44s ORF was amplified from LN229 cDNA using a HotStar HiFidelity Polymerase Kit (Qiagen Inc., Hilden, Germany). CD44s ORF was subcloned into pCAG−Ble−ssPA16 vector possessing signal sequence and N−terminal PA16 tag (GLEGGVAMPGAEDDVV) [19,47–51]. CHO/CD44s was established by transfecting pCAG−Ble/PA16−CD44s into CHO−K1 cells using a Neon transfection system (Thermo Fisher Scientific, Inc., Waltham, MA, USA). CD44v3−10 ectodomain (CD44ec)−secreting LN229 (LN229/CD44ec) was established by transfecting pCAG−Neo/PA−CD44ec−RAP−MAP into LN229 cells using the Neon transfection system. The amino acid sequences of the tag system in this study were as follows: PA tag [52–54], 12 amino acids (GVAMPGAEDDVV); RAP tag [55,56], 12 amino acids (DMVNPGLEDRIE); and MAP tag [57,58], 12 amino acids (GDGMVPPGIEDK).

LN229, KYSE70, and KYSE770 were cultured in Dulbecco’s Modified Eagle Medium (DMEM) complete medium, containing DMEM (4.5 g/L glucose) with L−Gln and without sodium pyruvate (Nacalai Tesque, Inc., Kyoto, Japan), 10% (v/v) heat−inactivated fetal bovine serum (FBS, Thermo Fisher Scientific Inc.), 100 U/mL of penicillin (Nacalai Tesque, Inc.), 100 µg/mL streptomycin (Nacalai Tesque, Inc.), 0.25 µg/mL amphotericin B (Nacalai Tesque, Inc.). LN229/CD44ec was cultured in DMEM complete medium, containing 0.5 mg/mL of G418 (Nacalai Tesque, Inc.).

P3U1 and CHO−K1 were cultured in Roswell Park Memorial Institute (RPMI)−1640 medium (Nacalai Tesque, Inc.) supplemented with 10% (v/v) FBS, 100 U/mL penicillin, 100 µg/mL streptomycin, and 0.25 µg/mL amphotericin B. CHO/CD44s was cultured in RPMI complete medium, including 0.5 mg/mL Zeocin (InvivoGen, San Diego, CA, USA). All cells were grown in a humidified incubator at 37 °C with 5% CO₂.

4.2. Purification of CD44ec

After LN229/CD44ec was cultured using DMEM complete medium without G418, CD44ec was purified from the supernatants using RAP tag system, comprised of an anti−RAP tag mAb (clone PMab−2) and a RAP peptide (GDDMVNPGLLEDRIE) [55,56]. The filtered culture supernatant (5 L) was passed through PMab−2−Sepharose (2 mL bed volume), and the same process was repeated three times. The beads were then washed with 100 mL of phosphate−buffered saline (PBS, Nacalai Tesque, Inc.), and eluted with 0.1 mg/mL of RAP peptide in a step−wise manner (2 mL × 10).

4.3. Hybridoma Production

Female BALB/c mice (6−weeks old) were purchased from CLEA Japan (Tokyo, Japan). The animals were housed under specific pathogen−free conditions. The Animal Care and Use Committee of Tohoku University approved all animal experiments.

A BALB/c mouse was immunized with CD44ec (150 µg) intraperitoneally (i.p.) with Imject Alum (Thermo Fisher Scientific Inc.). The procedure included three additional immunizations with CD44ec (2nd immunization, 150 µg; 3rd immunization, 100 µg; 4th
immunization, 50 µg) followed by a final booster injection of CD44ec (50 µg) two days prior to the harvest of splenic cells.

Subsequently, splenic cells were fused with P3U1 cells using polyethylene glycol 1500 (PEG1500; Roche Diagnostics, Indianapolis, IN, USA). The hybridomas were then grown in RPMI media supplemented with hypoxanthine, aminopterin, and thymidine (HAT) for selection (Thermo Fisher Scientific Inc.). The culture supernatants were screened for the anti-CD44ec antibody production using enzyme-linked immunosorbent assay (ELISA).

4.4. ELISA

CD44ec was immobilized on Nunc Maxisorp 96-well immunoplates (Thermo Fisher Scientific Inc.) at a concentration of 1 µg/mL for 30 min at 37 °C. After washing with PBS containing 0.05% (v/v) Tween 20 (PBST; Nacalai Tesque, Inc.), wells were blocked with 1% (w/v) bovine serum albumin (BSA)–containing PBST for 30 min at 37 °C. Culture supernatants were added to each well, followed by peroxidase–conjugated anti–mouse immunoglobulins (1:2000 diluted; Agilent Technologies Inc., Santa Clara, CA, USA). Enzymatic reactions were conducted using 1 Step Ultra TMB (Thermo Fisher Scientific Inc.) followed by the measurement of the optical density at 655 nm, using an iMark microplate reader (Bio–Rad Laboratories, Inc., Berkeley, CA, USA).

4.5. Flow Cytometry

Exponentially growing cells were collected following a brief exposure to 0.25% (w/v) trypsin and 1 mM ethylenediaminetetraacetic acid (Nacalai Tesque, Inc.). The cells were then washed with 0.1% (w/v) BSA in PBS and treated with C44Mab−46 for 30 min at 4 °C. After incubation, cells were treated with Alexa Fluor 488–conjugated anti–mouse IgG (1:2000; Cell Signaling Technology, Inc., Danvers, MA, USA). In the peptide blocking assay, C44Mab−46 (1 µg/mL) was incubated with 10 µg/mL of human CD44 peptide (amino acids 161−180, WT) or the D175A mutant peptide [21] for 30 min at 4 °C. CHO/CD44s cells were treated with C44Mab−46 + each peptide, and further treated with Alexa Fluor 488–conjugated anti–mouse IgG. Fluorescence data were collected using SA3800 Cell Analyzer (Sony Corp.) and analyzed using FlowJo software (BD Biosciences, Franklin Lakes, NJ, USA).

4.6. Determination of Dissociation Constant (K_D) by Flow Cytometry

CHO/CD44s, KYSE70, and KYSE770 cells were suspended in 100 µL serially–diluted anti–C44Mab−46 mAbs, after which 50 µL Alexa Fluor 488–conjugated anti–mouse IgG (1:200; Cell Signaling Technology, Inc.) was added. Fluorescence data were collected, using EC800 (Sony Corp., CHO/CD44s) or BD FACSLyric (KYSE70 and 770). The apparent K_D was calculated by fitting saturation binding curves to the built-in, one–site binding models in GraphPad PRISM 8 (GraphPad Software, Inc., La Jolla, CA, USA).

4.7. Western Blot Analysis

Cell lysates (10 µg) were boiled in sodium dodecyl sulfate (SDS) sample buffer (Nacalai Tesque, Inc.). Proteins were separated on 5–20% polyacrylamide gels (FUJIFILM Wako Pure Chemical Corporation) and transferred onto polyvinylidene difluoride (PVDF) membranes (Merck KGaA, Darmstadt, Germany). After blocking with 4% (w/v) skim milk (Nacalai Tesque, Inc.) in PBS with 0.05% (v/v) Tween 20, membranes were incubated with 1 µg/mL C44Mab−46 or 1 µg/mL anti–β−actin (clone AC−15; Sigma–Aldrich Corp., St. Louis, MO, USA). Membranes were then incubated with peroxidase–conjugated anti–mouse immunoglobulins (diluted 1:1000; Agilent Technologies, Inc.) to detect C44Mab−46 and anti–β−actin. Finally, protein bands were detected with a chemiluminescence reagent, ImmunoStar LD (FUJIFILM Wako Pure Chemical Corporation) using a Sayaca−Imager (DRC Co. Ltd., Tokyo, Japan).
4.8. Immunohistochemical Analysis

Paraffin-embedded ESCC tissue microarray (Product Code: BC02011, US Biomax Inc., Rockville, MD, USA) were deparaffinized in xylene and rehydrated. Then, they were autoclaved in citrate buffer (pH 6.0; Agilent Technologies Inc.) for 20 min. After blocking with SuperBlock T20 (Thermo Fisher Scientific, Inc.), sections were incubated with C44Mab-46 (5 µg/mL) for 1h at room temperature and then treated with the EnVision+ Kit for mouse (Agilent Technologies Inc.) for 30 min. Color was developed using 3,3′-diaminobenzidine tetrahydrochloride (DAB; Agilent Technologies Inc.) for 2 min. Counterstaining was performed with hematoxylin (FUJIFILM Wako Pure Chemical Corporation). Hematoxylin and eosin (HE) staining (FUJIFILM Wako Pure Chemical Corporation) was performed using consecutive tissue sections. Leica DMD108 (Leica Microsystems GmbH, Wetzlar, Germany) was used to examine the sections and obtain images.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms23105535/s1.

Author Contributions: N.G., T.T. and T.A. performed the experiments. M.K.K. and Y.K. designed the experiments. N.G. analyzed the data. N.G., H.S. and Y.K. wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported in part by AMED (grant numbers: JP22ama121008, JP21am0401013 (to Y.K.), JP22bm1004001 (to Y.K.), JP22ck0106730 (to Y.K.), JP21am0101078 (to Y.K.)).

Institutional Review Board Statement: The animal study protocol was approved by the Animal Care and Use Committee of Tohoku University (Permit number: 2019NiA-001) for studies involving animals.

Conflicts of Interest: The authors declare no conflict of interest involving this article.

References
1. Fox, S.B.; Fawcett, J.; Jackson, D.G.; Collins, I.; Gatter, K.C.; Harris, A.L.; Gearing, A.; Simmons, D.L. Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res. 1994, 54, 4539–4546. [PubMed]
2. Yan, Y.; Zuo, X.; Wei, D. Concise review: Emerging role of CD44 in cancer stem cells: A promising biomarker and therapeutic target. Stem Cells Transl. Med. 2015, 4, 1033–1043. [CrossRef] [PubMed]
3. Ponta, H.; Sherman, L.; Herrlich, P.A. CD44: From adhesion molecules to signalling regulators. Nat. Rev. Mol. Cell Biol. 2003, 4, 33–45. [CrossRef] [PubMed]
4. Chen, C.; Zhao, S.; Karnad, A.; Freeman, J.W. The biology and role of CD44 in cancer progression: Therapeutic implications. J. Hematol. Oncol. 2018, 11, 64. [CrossRef] [PubMed]
5. Bennett, K.L.; Jackson, D.G.; Simon, J.C.; Tanczos, E.; Peach, R.; Modrell, B.; Stamenkovic, I.; Plowman, G.; Aruffo, A. CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor. J. Cell Biol. 1995, 128, 687–698. [CrossRef]
6. Orian-Rousseau, V.; Chen, L.; Sleeman, J.P.; Herrlich, P.; Ponta, H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 2002, 16, 3074–3086. [CrossRef]
7. Ishimoto, T.; Nagano, O.; Yae, T.; Tamada, M.; Motohara, T.; Oshima, H.; Oshima, M.; Ikeda, T.; Asaba, R.; Yagi, H.; et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011, 19, 387–400. [CrossRef]
8. Slevin, M.; Krupinski, J.; Gaffney, J.; Matou, S.; West, D.; Delisser, H.; Savani, R.C.; Kumar, S. Hyaluronan-mediated angiogenesis in vascular disease: Uncovering RHAMM and CD44 receptor signaling pathways. Matrix Biol. 2007, 26, 58–68. [CrossRef] [PubMed]
9. Morath, I.; Hartmann, T.N.; Orian-Rousseau, V. CD44: More than a mere stem cell marker. Int. J. Biochem. Cell Biol. 2016, 81, 166–173. [CrossRef]
10. Hassn Mesrati, M.; Syafruddin, S.E.; Mohtar, M.A.; Syahir, A. CD44: A multifunctional mediator of cancer progression. Biomolecules 2021, 11, 1850. [CrossRef]
11. Murphy, J.F.; Lennon, F.; Steele, C.; Kelleher, D.; Fitzgerald, D.; Long, A.C. Engagement of CD44 modulates cyclooxygenase induction, VEGF generation, and proliferation in human vascular endothelial cells. FASEB J. 2005, 19, 446–448. [CrossRef] [PubMed]
12. Uchino, M.; Kojima, H.; Wada, K.; Imada, M.; Onoda, F.; Satōfuka, H.; Utsugi, T.; Murakami, Y. Nuclear beta-catenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells. BMC Cancer 2010, 10, 414. [CrossRef] [PubMed]
35. Kaneko, M.K.; Yamada, S.; Nakamura, T.; Abe, S.; Nishio, Y.; Kunita, A.; Fukayama, M.; Fujii, Y.; Ogasawara, S.; Kato, Y. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity. *Cancer Med.* 2017, 6, 768–777. [CrossRef] [PubMed]

36. Kato, Y.; Kaneko, M.K. A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. *Sci. Rep.* 2014, 4, 5924. [CrossRef]

37. Miyazaki, A.; Nakai, H.; Sonoda, T.; Hirohashi, Y.; Kaneko, M.K.; Kato, Y.; Sawa, Y.; Hiratsuka, H. LpMab-23-recognizing cancer-type podoplanin is a novel predictor for a poor prognosis of early stage tongue cancer. *Onco target* 2018, 9, 21156–21165. [CrossRef]

38. Kaneko, M.K.; Ohishi, T.; Kawada, M.; Kato, Y. A cancer-specific anti-podocalyxin monoclonal antibody (60-mG2a-f) exerts antitumor effects in mouse xenograft models of pancreatic carcinoma. *Biochem. Biophys. Rep.* 2020, 24, 100826. [CrossRef]

39. Kaneko, M.K.; Itai, S.; Yamada, S.; Kato, Y. 47-mG2a-Type of PcMab-47 Useful for detecting podocalyxin in esophageal cancers by immunohistochemistry. *Monoclon. Antib. Immunodiagn. Immunother.* 2018, 37, 158–161. [CrossRef]

40. Tanaka, M.; Kijima, H.; Shimada, H.; Makuuchi, H.; Ozawa, S.; Inokuchi, S. Expression of podoplanin and vimentin is correlated with prognosis in esophageal squamous cell carcinoma. *Mol. Med. Rep.* 2015, 12, 4029–4036. [CrossRef]

41. Nakashima, Y.; Yoshinaga, K.; Kitao, H.; Ando, K.; Kimura, Y.; Saeki, H.; Oki, E.; Morita, M.; Kakeji, Y.; Hirahashi, M.; et al. Podoplanin is expressed at the invasive front of esophageal squamous cell carcinomas and is involved in collective cell invasion. *Cancer Sci.* 2013, 104, 1718–1725. [CrossRef] [PubMed]

42. Rahadiani, N.; Ikeda, J.; Makino, T.; Tian, T.; Qiu, Y.; Mamat, S.; Wang, Y.; Doki, Y.; Aozasa, K.; Morii, E. Tumorigenic role of podoplanin in esophageal squamous-cell carcinoma. *Ann. Surg. Oncol.* 2010, 17, 1311–1323. [CrossRef] [PubMed]

43. Suzuki, H.; Kaneko, M.K.; Kato, Y. Roles of podoplanin in malignant progression of tumor. *Cells 2022, 11, 575. [CrossRef] [PubMed]

44. Takei, J.; Kaneko, M.K.; Ohishi, T.; Hosono, H.; Nakamura, T.; Yanaka, M.; Sano, M.; Asano, T.; Sayama, Y.; Kawada, M.; et al. A defucosylated antiCD44 monoclonal antibody 5mG2af exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma. *Oncol. Rep.* 2020, 44, 1949–1960. [CrossRef]

45. Shimada, Y.; Imamura, M.; Waga, T.; Yamaguchi, N.; Tobe, T. Characterization of 21 newly established esophageal cancer cell lines. *Cancer 1992, 69, 277–284. [CrossRef]

46. Hayatsu, N.; Ogasawara, S.; Kaneko, M.K.; Kato, Y.; Narimatsu, H. Expression of highly sulfated keratan sulfate synthesized in human glioblastoma cells. *Biochem. Biophys. Res. Commun.* 2008, 368, 217–222. [CrossRef]

47. Furusawa, Y.; Yamada, S.; Itai, S.; Sano, M.; Nakamura, T.; Yanaka, M.; Handa, S.; Mizuno, T.; Maeda, K.; Fukui, M.; et al. Establishment of monoclonal antibody PMab-202 against horse podoplanin. *Monoclon. Antib. Immunodiagn. Immunother.* 2018, 37, 233–237. [CrossRef]

48. Furusawa, Y.; Yamada, S.; Itai, S.; Sano, M.; Nakamura, T.; Yanaka, M.; Fukui, M.; Harada, H.; Mizuno, T.; Sakai, Y.; et al. PMab-210: A monoclonal antibody against pig podoplanin. *Monoclon. Antib. Immunodiagn. Immunother.* 2019, 38, 30–36. [CrossRef]

49. Kato, Y.; Yamada, S.; Furusawa, Y.; Itai, S.; Nakamura, T.; Yanaka, M.; Sano, M.; Harada, H.; Fukui, M.; Kaneko, M.K. PMab-213: A monoclonal Antibody for Immunohistochemical Analysis Against Pig Podoplanin. *Monoclon. Antib. Immunodiagn. Immunother.* 2019, 38, 18–24. [CrossRef]

50. Furusawa, Y.; Yamada, S.; Itai, S.; Sano, M.; Nakamura, T.; Yanaka, M.; Sano, M.; Harada, H.; Fukui, M.; Kaneko, M.K.; Kato, Y. PMab-219: A monoclonal antibody for the immunohistochemical analysis of horse podoplanin. *Biochem. Biophys. Rep.* 2019, 18, 100616. [CrossRef]

51. Furusawa, Y.; Yamada, S.; Itai, S.; Nakamura, T.; Takei, J.; Sano, M.; Harada, H.; Fukui, M.; Kaneko, M.K.; Kato, Y. Establishment of a monoclonal antibody PMab-233 for immunohistochemical analysis against Tasmanian devil podoplanin. *Biochem. Biophys. Rep.* 2019, 18, 100631. [CrossRef] [PubMed]

52. Tamura, R.; Oi, R.; Akashi, S.; Kaneko, M.K.; Kato, Y.; Nogi, T. Application of the NZ-1 Fab as a crystallization chaperone for PA tag-inserted target proteins. *Proteins 2019, 28, 823–836. [CrossRef] [PubMed]

53. Fujiy, Y.; Matsunaga, Y.; Arimori, T.; Kitago, Y.; Ogasawara, S.; Kaneko, M.K.; Kato, Y.; Takagi, J. Tailored placement of a turn-forming PA tag into the structured domain of a protein to probe its conformational state. *J. Cell Sci.* 2016, 129, 1512–1522. [CrossRef] [PubMed]

54. Fujiy, Y.; Kaneko, M.; Neyazaki, M.; Nogi, T.; Kato, Y.; Takagi, J. PA tag: A versatile protein tagging system using a super high affinity antibody against a dodacopeptide derived from human podoplanin. *Protein Expr. Purif.* 2014, 95, 240–247. [CrossRef]

55. Miura, K.; Yoshida, H.; Nosaki, S.; Kaneko, M.K.; Kato, Y. RAP Tag and PMab-2 antibody: A tagging system for detecting and purifying proteins in plant cells. *Front. Plant Sci.* 2020, 11, 510444. [CrossRef] [PubMed]

56. Fujiy, Y.; Kaneko, M.K.; Ogasawara, S.; Yamada, S.; Yanaka, M.; Nakamura, T.; Saidob, N.; Yoshida, K.; Honma, R.; Kato, Y. Development of RAP Tag, a Novel Tagging System for Protein Detection and Purification. *Monoclon. Antib. Immunodiagn. Immunoother.* 2017, 36, 68–71. [CrossRef]

57. Fujiy, Y.; Kaneko, M.K.; Kato, Y. MAP Tag: A Novel Tagging System for Protein Purification and Detection. *Monoclon. Antib. Immunodiagn. Immunoother.* 2016, 35, 293–299. [CrossRef]

58. Wakasa, A.; Kaneko, M.K.; Kato, Y.; Takagi, J.; Arimori, T. Site-specific epitope insertion into recombinant proteins using the MAP tag system. *J. Biochem. 2020, 168, 375–384. [CrossRef]